Canada markets open in 2 hours 19 minutes

CytoDyn Inc. (CYDY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8000+0.0114 (+1.45%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.7886
Open0.8201
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7800 - 0.8398
52 Week Range0.2300 - 2.5400
Volume1,935,676
Avg. Volume2,621,830
Market Cap648.576M
Beta (5Y Monthly)-0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.2250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

    VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022. Dr. Arman will be responsible for determining and leading the Company’s operating strategy for the future. It is anticipated that he will advance to Chief Executive Officer and

  • GlobeNewswire

    CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

    $5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV VANCOUVER, Washington, July 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a new, preclinical study in nonhuman primates that will evaluate the potential use in HIV of a

  • GlobeNewswire

    CytoDyn to Hold Webcast to Provide a Quarterly Company Update

    VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research & Developm